Apatinib in refractory radiation-induced brain edema
نویسندگان
چکیده
RATIONALE Apatinib is a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor-2, which has observed to be effective and safe in refractory radiation-induced brain edema, like Avastin did. Till now, there is no case report after apatinib came in the market. PATIENT CONCERNS Two patients who received brain radiotherapy developed clinical manifestations of brain edema, including dizziness, headache, limb activity disorder, and so on. DIAGNOSES Two patients were both diagnosed as refractory radiation-induced brain edema. INTERVENTIONS Two patients received apatinib (500 mg/day) for 2 and 4 weeks. OUTCOMES Two patients got symptomatic improvements from apatinib in different degrees. Magnetic resonance imaging after apatinib treatments showed that compared with pre-treatment imaging, the perilesional edema reduced dramatically. However, the toxicity of apatinib was controllable and tolerable. LESSONS Apatinib can obviously relieve the symptoms of refractory radiation-induced brain edema and improve the quality of life, which offers a new method for refractory radiation-induced brain edema in clinical practices. But that still warrants further investigation in the prospective study.
منابع مشابه
Successful treatment with apatinib for refractory recurrent malignant gliomas: a case series
Malignant glioma (MG) is a common and refractory primary tumor with a high recurrence rate. There is still a lack of effective therapy for recurrent MG (rMG). We present here two cases of refractory rMG treated using apatinib, which is a new highly selective inhibitor to VEGFR. Case 1, a 37-year-old female, was diagnosed with recurrent intracerebral high-grade glioma and failed to almost all tr...
متن کاملConcurrent apatinib and local radiation therapy for advanced gastric cancer
RATIONALE Apatinib is a novel anti-angiogenic agent targeting vascular endothelial growth factor receptor-2, which is effective in patients with chemotherapy-refractory gastric cancer. There are no reports of concurrent apatinib with local radiation therapy in elderly patients with advanced gastric cancer. PATIENT CONCERNS AND DIAGNOSES:: we present the first published report of a 70-year-old m...
متن کاملEstablishment of a rat model of radiation-induced lung injury
Background: Radiation-induced lung injury is a refractory side effect in lung cancer radiotherapy, the mechanism still remains unclear, hence an appropriate animal mode may become useful to investigate it. Materials and Methods: 50 female Wistar rats were randomly divided into 5 groups, average 10 rats/cage: A. control group B. 3Gy×10f C. 6Gy×5f D. 12.5Gy×1f E.15.3Gy×1f....
متن کاملApatinib treatment combined with chemotherapy for advanced epithelial ovarian cancer: a case report
Apatinib is a novel oral tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor-2, which has been proved by clinical trials to be effective and safe for patients with chemotherapy-refractory gastric cancer. To date, there is no study or case report on apatinib treatment for patients with ovarian cancer. Here, we present the case of a 50-year-old Chinese woman with advan...
متن کامل